Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study
W Xu, K Zhou, T Wang, S Yang, L Liu… - American Journal of …, 2023 - Wiley Online Library
Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase
inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with …
inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with …
[HTML][HTML] Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors
S Molica, D Allsup - Cancers, 2025 - mdpi.com
Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a
shift from historical chemotherapeutic regimens to targeted therapies such as Bruton …
shift from historical chemotherapeutic regimens to targeted therapies such as Bruton …
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising
efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B …
efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B …
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with …
RAB Nunes, Á Avezum, M de Oliveira Marques… - Annals of …, 2024 - Springer
Bruton tyrosine kinase (BTK) inhibitors play an important role in targeted treatment of B-cell
lymphoproliferative disorders. However, adverse events may limit the proper course of …
lymphoproliferative disorders. However, adverse events may limit the proper course of …
Komplexní hodnocení imunitních defektů u nemocných s chronickou lymfocytární leukémií
P Vodárek - 2023 - dspace.cuni.cz
Komplexní hodnocení imunitních defektů u nemocných s chronickou lymfocytární leukémií
MUDr. Pavel Vodárek Abstrakt disertační práce Chronická lymfocytární leukémie (CLL) je …
MUDr. Pavel Vodárek Abstrakt disertační práce Chronická lymfocytární leukémie (CLL) je …
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials
S Molica, D Allsup - Expert Review of Anticancer Therapy, 2024 - Taylor & Francis
Introduction Chronic lymphocytic leukemia (CLL) management has witnessed a
transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal …
transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal …
[PDF][PDF] PRIMARY BREAST LYMPHOMA: A RARE CASE REPORT
B Selvaraj, SS Mathew, KL Jayakumar… - Int J Acad Med …, 2024 - academicmed.org
Primary lymphoma of breast is commonly characterized as lymphoma localized to one or
both of the breasts and/or the regional lymph nodes in the absence of a previous history of …
both of the breasts and/or the regional lymph nodes in the absence of a previous history of …